

10th November, 2016

BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Listing Department Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
---	--

Dear Sirs,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 [SEBI (LODR) Regulations, 2015]

We wish to inform you that the Board of Directors of the Company, at their Meeting held on 10th November, 2016, approved the acquisition of 100% stake in Wockhardt France (Holdings) S.A.S. ('WFH') (an existing step down subsidiary of the Company) from Wockhardt Bio AG ('WBG'), a subsidiary of the Company. By virtue of the said acquisition, WFH shall become a direct wholly owned subsidiary of the Company from erstwhile step down subsidiary. WBG continues to be a direct subsidiary of the Company.

The details required under Regulation 30 and Para A of Part A of Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are given in the enclosed **Annexure**.

Kindly take the above information on record.

Thanking You,

For Wockhardt Limited



Narendra Singh
Company Secretary

Encl: As above



Sl. No.	Details of Events that need to be provided	Information of such event(s)								
1.	Name of the target entity, details in brief such as size, turnover etc.;	Wockhardt France (Holdings) S.A.S. ('WFH') A step down subsidiary of the Company								
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	No.								
3.	Industry to which the entity being acquired belongs	Pharmaceuticals, in line with the business of the Company.								
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	WFH will become a direct subsidiary of the Company from a step down subsidiary.								
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Requisite approval(s), if any.								
6.	Indicative time period for completion of the acquisition	March, 2017								
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash								
8.	Cost of acquisition or the price at which the shares are acquired	Being acquisition of shares of a step down subsidiary, at Book Value.								
9.	Percentage of shareholding/ control acquired and / or number of shares acquired	100%								
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	WFH, incorporated in France, is an existing subsidiary of WBG, a direct subsidiary of the Company. WFH is the holding company of Laboratoires Pharma 2000 S.A.S, Laboratoires Negma S.A.S., Niverpharma S.A.S., Phytex S.A.S. and Negma Beneulex S.A. All these Companies are incorporated in France except for Negma Beneulex S.A. which is incorporated in Belgium.								
		Rs. in crore								
		<table border="1"> <thead> <tr> <th>Particulars</th> <th>FY 2015-16</th> <th>FY 2014-15</th> <th>FY 2013-14</th> </tr> </thead> <tbody> <tr> <td>Turnover</td> <td>0.50</td> <td>0.48</td> <td>Nil</td> </tr> </tbody> </table>	Particulars	FY 2015-16	FY 2014-15	FY 2013-14	Turnover	0.50	0.48	Nil
Particulars	FY 2015-16	FY 2014-15	FY 2013-14							
Turnover	0.50	0.48	Nil							

